New capacity fuels Provenge sales growth

Dendreon has reported $15 million in sales of its new prostate cancer vaccine Provenge for the month of April, reflecting its recently expanded production capacity. The company won FDA approval last month for 36 additional workstations to produce Provenge. Report

Suggested Articles

With tens of millions of Americans tuned into Tuesday’s presidential debate, the race for a COVID-19 vaccine took center stage in a big way.

A $300M pandemic ad campaign may be falling apart as HHS employees push back, celebrities balk and agency brass push a rushed timeline, Politico says.

With a pack of drugmakers angling for COVID-19 vaccine approvals in the coming months, the task of global distribution is more important than ever. Wi